*CONTENT WARNING – discussion of use of animals in research*
Triple negative breast cancer is notoriously difficult to treat – it lacks the receptors that would allow it to respond to many of the drugs used for other forms of breast cancer. However, for the first time, a new drug candidate has been designed using genetic sequencing to specifically trigger tumour cells into killing themselves, leaving healthy cells untouched.
Difficult to treat
As many as 10-20% of all breast cancers can be defined as triple negative breast cancers. This type of breast cancer doesn’t have estrogen, progesterone, or HER2 receptors. And because it doesn’t have these receptors, it doesn’t respond to hormonal therapies or to treatments that target HER2 receptors (e.g. Herceptin), which are often used to treat other types of breast cancer.
In other words, it won’t respond to therapies that “starve” the cancer cells of their energy. It also tends to be more aggressive. Therefore, people suffering from this form of the disease are usually treated with more toxic forms of chemotherapy, combined with surgery and radiation.
Because as many as 10-20% of all breast cancers are triple negative, there is intense research in the area.
New drug candidate
A paper being published in the Proceedings of the National Academy of Science by a team from The Scripps Research Institute (TSRI) this week, however, describes a new drug candidate that has been shown to decrease the growth of tumour cells in animal models.
The study demonstrates that a compound known as Targaprimir-96 triggers breast cancer cells to kill themselves. It does this by specifically targeting a folded section of micro ribonucleic acid (microRNA) that is involved in “igniting” the cancer.
The breast cancer cells – and importantly, not healthy cells – then kill themselves via a process called programmed cell death.
MicroRNAs are short molecules that work within all animal and plant cells, typically functioning as a “dimmer switch” for one or more genes. Various microRNAs have been associated with diseases. The target of the study, microRNA-96, promotes cancer by discouraging programmed cell death, which can rid the body of cells that grow out of control.
TSRI Professor Matthew Disney, leader of the study, says:
This is the first example of taking a genetic sequence and designing a drug candidate that works effectively in an animal model against triple negative breast cancer
Disney credits the successful study to advances in precision medicine, an emerging approach to treat and prevent disease in a more customised way:
The study represents a clear breakthrough in precision medicine, as this molecule only kills the cancer cells that express the cancer-causing gene—not healthy cells. These studies may transform the way the lead drugs are identified—by using the genetic makeup of a disease.
In the study, the drug candidate was tested in animal models over a period of 21 days. The results showed decreased production of microRNA-96 and increased programmed cell death, which significantly reduced tumour growth. Healthy cells were unaffected.
In contrast, Disney noted, a typical cancer therapeutic targets and kills cells indiscriminately, often leading to side effects that can make these drugs difficult for patients to tolerate.
Precision medicine, in the past, has typically involved time-consuming and expensive high-throughput screens to test millions of potential drug candidates to identify those few that affect the target of interest.
The team from TSRI, however, used an approach that eliminates these screens. The new study uses the lab’s computational approach called Inforna, which focuses on developing designer compounds that bind to RNA folds, particularly microRNAs.
First author of the study and member of the Disney lab, Research Associate Sai Pradeep Velagapudi added:
In the future we hope to apply this strategy to target other disease-causing RNAs, which range from incurable cancers to important viral pathogens such as Zika and Ebola.
While clearly preliminary, the study shows how precision medicine has come along in leaps and bounds and offers a glimmer of hope for those suffering from this difficult to treat cancer.
Full article information: Sai Pradeep Velagapudi et al., “Design of a Small Molecule Against an Oncogenic Non-coding RNA” Proceedings of the National Academy of Sciences, published online ahead of print on May 9, 2016.
Featured image via Flickr / F. // Chicca // K. Silva
We need your help to keep speaking the truth
Every story that you have come to us with; each injustice you have asked us to investigate; every campaign we have fought; each of your unheard voices we amplified; we do this for you. We are making a difference on your behalf.
Our fight is your fight. You’ve supported our collective struggle every time you gave us a like; and every time you shared our work across social media. Now we need you to support us with a monthly donation.
We have published nearly 2,000 articles and over 50 films in 2021. And we want to do this and more in 2022 but we don’t have enough money to go on at this pace. So, if you value our work and want us to continue then please join us and be part of The Canary family.
In return, you get:
* Advert free reading experience
* Quarterly group video call with the Editor-in-Chief
* Behind the scenes monthly e-newsletter
* 20% discount in our shop
Almost all of our spending goes to the people who make The Canary’s content. So your contribution directly supports our writers and enables us to continue to do what we do: speaking truth, powered by you. We have weathered many attempts to shut us down and silence our vital opposition to an increasingly fascist government and right-wing mainstream media.
With your help we can continue:
* Holding political and state power to account
* Advocating for the people the system marginalises
* Being a media outlet that upholds the highest standards
* Campaigning on the issues others won’t
* Putting your lives central to everything we do
We are a drop of truth in an ocean of deceit. But we can’t do this without your support. So please, can you help us continue the fight?